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Abstract
Peptides exhibit properties based on the amino acids present in the peptide and 
structure the peptide assumes in its environment. For example, peptides have been 
shown to be antimicrobial when they are amphipathic and in an a-helical shape. The 
mechanism for this antimicrobial activity is subject to dispute. One theory states that 
the peptides work by forming a “pore” through the cell membrane which causes a 
depolarization of the membrane and the cell lysis because of osmosis. Another theory 
states that the peptides merely compromise the integrity of the membrane by 
solubilizing the membrane.
In order for the “pore” theory of lytic activity to occur, the peptides must arrange 
themselves in a discrete aggregated fashion. The goal of this research is to explore the 
nature of the aggregated state of designed peptides through the use of CD spectroscopy 
and fluorescent labeling.
Several peptides were designed using a minimalist approach and were measured 
using CD spectroscopy to explore how the placement of leucines in the peptides cause a 
change in their propensity for aggregation. Using this information, the site for an 
incorporation of a fluorescently labeled peptide was chosen.
The synthesis of the fluorescently labeled amino acid presented an opportunity to 
explore different types of glycine templates and to find a quicker method for making 
the amino acid in high yields. After the synthesis of the amino acid, it was incorporated 
into the peptides and CD and fluorescence studies were accomplished. The result shows 
the peptides, when aggregated, align themselves in an antiparallel fashion.
vii
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1.1 Introduction
The use of antibiotics has caused a general increase in the good health of the 
people of the world. However, the microbes for which these antibiotics are intended 
have been slowly building resistance. This has caused a general alarm in the medical 
field and has spurred research into finding alternatives to the traditional antibiotics. One 
such alternative has been the use of lytic peptides which can selectively destroy 
microbes. However, the mechanism by which they destroy pathogens is in dispute. 
This thesis will attempt to explain the mechanism of interaction while designing novel 
lytic peptides for possible drug use.
1.2 Definition of Amphipathicity and Aggregation
Some peptides possess the ability to be amphipathic when in an a-helical form. 
An amphipathic a-helix has all the polar residues aligned on one side of the a-helical 
axis. Figure 1.2.1 shows a side view of an amphipathic peptide in an a-helical 
conformation while Figure 1.2.2 shows a longitudinal view of an amphipathic a-helix.
Amphipathic peptides may aggregate. This is best described with this idea of 
solubility. In an aqueous environment, an amphipathic peptide will want to associate, 
or aggregate, with another peptide in order for the nonpolar residues of the peptides to 
solubilize one another. In the case of an aqueous environment, the nonpolar portion of 
the peptide will be sequestered within the peptide aggregate while the polar portions 
will be sequestered on the exterior of the peptide aggregate. Figure 1.2.3 shows four 
amphipathic a-helical peptides aggregated in an aqueous environment.
l
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Figure 1.2.1: Side view of an amphipathic a-helix P represents polar residues 
while N represents nonpolar residues
Figure 1.2.2: Longitudinal view of an amphipathic a-helical peptide where 
P represents Polar residues while N represents Nonpolar residues
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Figure 1.2.3: Representation of an aggregated amphipathic a-helical peptide in an 
aqueous environment P represents Polar residues while N represents Nonpolar residues
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4An analogous peptide aggregate can form in a membrane. If  four peptides aggregate in a 
membrane, all the positive charges are on the inner part of the assembly while the 
nonpolar residues of the peptides interact with the nonpolar regions on the membrane. 
Figure 1.2.4 represents four peptides aggregating in an membrane environment where P 
represents polar residues and N represents nonpolar residues. This is one theory which 
addresses the lytic properties o f an amphipathic peptide. The peptide's polar 'inner circle' 
provides an aqueous environment which can span the hydrophobic part of the 
membrane. The aqueous environment allows water and ions to freely flow to the 
cytoplasm of the cell, depolarizing the membrane and causing the cell to rupture. 
Because of the ability of amphipathic peptides to lyse cells, nature uses them as part of 
noncellular immune response. Two of these types of peptides discovered are Melittin 
and Cecropin.
1.3 Melittin
1.3.1 Discovery and Physical properties
Melittin, a lytic peptide isolated from the venom of the bee Apis mellifera*, 
consists of 26 amino acids with a highly basic C-terminus region with a net charge of 6+ 
and a hydrophobic N-terminus region. It contains four separate parts: N-terminus a- 
heix, the flexible “hinge” region, the central a-helix and the positively charged C- 
terminus region2.
When in an a-helical shape, melittin has the property of amphipathicity; the 
polar region will align mostly on one side of the peptide while the nonpolar region will
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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Figure 1.2.4: Representation of the amphipathic a-helical peptides in an membrane 
environment. P represents Polar residues while N represents nonpolar residues
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be on the opposite side of the side of the peptide (see figure 1.3.1). This is not perfectly 
longitudinal due to the proline-14 located in the center of the peptide. The proline-14 
causes a bend in the peptide due to the structure of the amino acid hence the “hinged” 
region of the peptide.
The amphipathicity of melittin causes the peptide to demonstrate certain 
properties1. Melittin is soluble in aqueous solutions. This solubility causes the 
hydrophobic region of the amphipathic peptide to aggregate into a tetrameric form. The 
proximity of the positive charges from the lysines in this self-associated state results in 
a natural repulsion to self-association. The contribution of charge repulsion in an 
aggregated peptide, when the charge is increased from +4 to +6 by varying ionic 
strength, is about 600cal/(charge*mol of tetrameric melittin)3. Aggregation can be 
promoted, or inhibited in melittin by exploiting these contradictory properties.
Anything which suppresses charge formation on the lysine side chains promotes 
aggregation of the peptides. Solutions with increasing ionic strength promote 
aggregation by providing a counterion for the (+) charges on the lysines which 
effectively screen the charge.1 The nature of the counterion is also a factor in the 
aggregation of melittin. It has been found that the use of a divalent ion, such as Na2S0 4 , 
is more effective at promoting aggregation than univalent salts4. With the use of 
Na2SC>4, Schwarz explored the nature of the formation of tetramers using stop-flow 
techniques and found that dimerization was the slow step in aqueous self-association, 
while dimer-dimer interactions to form tetramers were diffusion controlled4. However 
the use of multivalent ions is questioned since multivalent ions form tight interactions 
with the peptide which are not compatible with helix formation5.
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Figure 1.3.1: Edmundson Helical wheel of Melittin
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Aggregation is also promoted by changing the pH By increasing the pH of the 
aqueous solution, the lysine side chains are deprotonated, reducing charge and 
promoting aggregation. Since melittin has three s-amino [Lys-7, Lys-21, Lys-23] and 
two E-guanidine [Arg-22, Arg-24] titratable groups, the stepwise titration has been 
reported.5 The ionic strength of a solution factors into the influence of the pH on 
melittin. It has been found that there are two stepwise alkaline transitions when melittin 
starts at low ionic strength and three at high ionic strength.
A study was also done to explore the charge type vs. a-helicity of the melittin. 
In one case, a negatively charged analogue of melittin was synthesized and the a- 
helicity of the melittin analogue was then measured in varying pH, ionic strength and 
temperature CD studies.6 A marked decrease in the a-helix propensity of anionic 
melittin was noted in all conditions. The authors postulated that this was due to the fact 
that negative charges were in closer proximity compared to the analogous positive 
charges on melittin. This therefore increased the helix-breaking propensity of the polar 
region of melittin.6
1.3.2 Determination of structure via NMR and crystallography
The structure of melittin was determined by high-resolution NMR spectroscopy. 
In methanol it was found to adopt an a-helical monomeric form.1 This study also 
showed that there was a relaxation of the a-helicity around the Leu-13-pro-14 region 
due to the ‘bending’ nature of the proline. The regions of a-helicity had characteristic 
NOE’s while it was noted that towards the end of the peptides, the NOE’s were not as 
prevalent. The conclusion was that the a-helicity of melittin was more relaxed at the 
ends than in the center of the peptide with the exception of the region that contains the
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
9proline. Melittin was also crystallized in an medium of high ionic strength and the X-ray 
crystal structure was solved. Under these conditions, melittin adopts an a-helical 
conformation.1
1.3.3 Theories for the mechanism of lytic activity o f Melittin
The mechanism of hemolytic activity of melittin is subject to debate. One theory 
suggests that melittin binds to the surface of a membrane. It then buries into the surface 
of the membrane through hydrophobic interaction. When four peptides are similarly 
buried and in proximity to one another, it forms a transmembrane pore which causes 
lysis via depolarization of the membrane and subsequent osmotic pressure. Figure 1.3.2 
illustrates this mechanism.
Another theory about the hemolytic activity of melittin is that the membrane 
permeability of the peptides cause destruction by micellization of patches of the 
membrane.1 This is similar to detergent solubilization. The binding of the peptide and 
burying of the peptide into the membrane is similar to that of the pore formation theory. 
Figure 1.3.3 illustrates this mechanism. Evidence for both theories will be presented in 
the following sections.
1.3.4 Voltage dependence and the pore mechanism for lytic activity
Melittin shows evidence of a pore formation in a membrane with an applied 
voltage gradient.1 The application of a potential across a membrane in the presence of a 
critical concentration of melittin shows a depolarization of the membrane caused by Na+ 
ion permeability. Depolarization of the membrane increases in a stepwise fashion as the 
fourth order of melittin concentration. This indicates that the melittin is coming 
together in a tetrameric form l.
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Figure 1.3.2: Mechanism for Melittin pore formation via the “pore” method
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Figure 1.3.3: Mechanism of Melittin “rafting” formation
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1.3.5 Effects of lipid concentration
The binding efficiencies of melittin to different types of membranes have also 
been studied. Many studies have been done on the nature and binding affinities of 
melittin to various micelles and membranes. Because of the amphipathicity of melittin, 
the hydrophobic region of melittin interacts with the lipid membrane. Membranes tend 
to promote a-helical secondary structure in melittin through hydrophobic interaction 
and melittin was found to bind to a membrane as a monomer.1 The binding of melittin 
to a membrane was studied as a function of pH and it was determined that binding 
increased at increased pH.7 Increased pH decrease the amount of charge on the lysines 
causing easier binding to the membranes.
Studies have been done to determine the orientation of the peptide in a 
membrane after it has bound to the membrane. Determining the orientation of melittin 
by fluorescence of the tryptophan showed that the tryptophan orientation existed to two 
forms: it was either embedded in the hydrophobic membrane close to the phospholipid 
headgroups, or it was exposed to the solvent system8.
The binding efficiencies of melittin to phophatidylglycerol/phosphatidylcholine 
membrane showed that there is a greater binding efficiency to this membrane due to 
presence of negative charges on the membrane 9. Melittin, in this type of membrane, 
also reoriented it. The presence of extra negative charge in the membrane caused the 
N+ charges of the phosphatidylcholine to orient towards the hydrophobic regions. The 
addition of melittin caused the N+ charges to reorient towards the aqueous media. This 
is found in the addition of melittin to phosphatidylcholine membranes. Melittin was 
also introduced to membranes which contain unsaturated tail groups 10. It was found
perm ission o f the copyright owner. Further reproduction prohibited without perm ission.
that there was a faster leakage of contents in the membrane containing unsaturated 
bonds. The authors speculated that was not due to the nature of the membrane, but 
because of the perturbation of the melittin in the membrane. Binding studies of melittin 
were also done on reversed micelles lI. Again it was found that melittin binds to the 
hydrophilic surface of reversed micelles and that it binds in a monomer form.
The binding of melittin caused leakage of the membranes without the presence 
of a voltage gradient at lytic concentrations is evidence that lytic activity could be 
caused by the solubilization of the membrane.
1.4 Cecropin
1.4.1 Physical properties of cecropin and analogues
Cecropin A, a peptide isolated from the Hylophora cecropia moth, acts as the 
moth's immune system 12. The same moth contained cecropin-like peptides subsequently 
named cecropin B 13 and cecropin D 14 which Merrifield synthesized by via solid phase 
peptide synthesis. Merrifield first synthesized a fraction of the cecropin A peptide 
consisting of the first 33 residues. 15 This synthetic peptide proved only slightly less 
effective as an antimicrobial peptide than the full length peptide.
All the cecropins share certain similarities. They consist of 31 and 39 amino 
acids, have strongly basic hydrophilic regions near the N-terminus and hydrophobic 
regions near the C-terminus.13 These two regions are separated by a central part that 
contains the a-helix breaking sequence of glycine and proline. An Edmundson helical 
wheel of Cecropin A, consisting of 37 amino acids is shown in figure 1.4.1. The 
structure of the peptides were determined by NMR and CD to have a-helical character 
in 15% HFIP.'6
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A cecropin analogue has also been isolated in mammals. The analogous peptide, 
named cecropin PI, was isolated from pig intestine. Because of this discovery, Boman 
theorizes that cecropin like peptides may be present in other mammals as a means of 
regulating bacterial growth in animals.17 Though analogous to the other cecropins, 
cecropin PI does not contain the central a-helix breaking sequence of glycine and 
proline common to the other cecropins.18
1.4.2 Aggregation of Cecropin
Cecropins has an amphipathic a-helical structure with the polar region 
containing predominantly positive charges. Consequently hydrophobic interactions of 
the a-helix promotes aggregation in neutral conditions, electrostatic repulsion of like- 
charged amino acids diminish aggregation. Therefore the use of any system, whether 
pH, ionic strength or fluorinated solvents, that suppresses the charge associated with the 
peptide and will promote the formation of aggregated peptides. This has been 
determined with cecropin by CD and ESR 19. Cecropin AD, a hybrid of cecropin A and 
cecropin D, aggregated in the presence of 5-10% (v/v) HFIP. The researches also 
showed that increasing the concentration of cecropin in 5-10% HFIP does not increase 
aggregation. Moreover, decreasing the concentration in the above conditions does not 
have any effect on the monomer- aggregate equilibrium19. The peptides also exhibited 
aggregate formation in the presence of high salt concentration (1.0 M NaCl) and high 
pH 15.
1.4.3 Voltage dependent ion channel formation.
Cecropin, at antimicrobial concentrations, formed channels through planar lipid 
membranes with a negative potential across the membrane. Channel formation is
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 1.4.1: Edmundson Helical wheel o f Cecropin A
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decreased in analogous peptides which do not have the hinged region present 20. The 
authors suggest that the insertion of the hydrophobic region of the amphipathic peptide 
and subsequent channel formation is dependent on the hinged region of the peptide. 
However the central hinged region is not necessary for lytic activity since it is not 
present in cecropin P I18. Molecular modeling found that cecropin possesses the 
possibility o f two types of transmembrane pores 21. Without an applied potential, the 
predicted pore forms with the nonpolar C-terminus buried in the lipid bilayer while the 
hydrophilic N-terminus is associated with the phospholipid headgroups. While with an 
applied potential, the ion channel is formed with the hydrophilic N-terminus group 
actually forming the channel. This hypothesis is not supported by experimental data.
1.4.4 Interactions of Cecropin with lipid bilayers
The controversy over the mechanism of action of lytic activity, by pore 
formation or membrane permeability, exists for cecropins. The cecropins seem to bind 
to a lipid bilayer as a monomer. Cecropin B2, a cecropin derivative isolated from the 
silkworm Bombyx moris, supposedly causes disintegration of the membrane leading to 
membrane permeation22. This was determined by the use of spectroscopic dyes placed 
on the cecropin B2. The concentration of cecropin needed to lyse the liposome can be 
correlated with the amount needed to lyse a bacteria and it was concluded that cecropin 
coats the bacteria before lysis occurs [Merrifield, 1988 #157]. However, the study was 
done on neutral liposomes. It is possible that on a neutral membrane, the action 
involving membrane permeation is possible while on a membrane containing a distinct 
potential, the pore formation is predominant.
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1.5 Modifications on naturally occurring peptides
The use of Cecropin as a possible antibiotic proves to be cost prohibitive due to 
the length of the peptide. Melittin, on the other hand, is smaller and less costly to 
produce, but its property of lysing erythrocytes makes it useless as a drug. Therefore 
scientists have experimented with hybrids in order to combine the broad spectrum 
antibiotic character of the cecropins with the shorter length o f melittin while trying to 
suppress melittin’s property of lysing erythrocytes.
One o f the first hybrids synthesized was the combination of Cecropin A and 
Cecropin D 23. This consisted of combining the amino acids 1-11 of cecropin A with 
amino acids 12-37 of Cecropin D. From this study, Fink and coworkers confirmed the 
importance of the highly basic amphipathic a-helix have in the antimicrobial activity. 
With this, more ambitious hybrids were made in order to decrease the size of the 
peptides.
The first highly successful peptide hybrid combined the basic residues of 
cecropin A (1-13) with the hydrophobic residues of melittin (1-13) 24. The result was 
better antibacterial activity compared to the parent peptides even when their overall size 
was decreased to 26 amino acids which represents a 30% decrease compared to 
cecropin24. Figure 1.5.1 shows a table comparing the antimicrobial activity of the parent 
peptides with various hybrids of cecropin and melittin. The authors were trying to 
follow the basic structural components found in the lytic peptides which are a basic 
amphipathic a-helix, a flexible segment between helices and a hydrophobic a-helix24. 
Manipulation of the peptide sequence showed that the removal of the Gly Pro hinge 
region caused an overall increase in bioactivity24. The NMR showed that the peptide
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forms an a-helical structure25. Throughout the studies, the authors assumed that the 
mechanism for lytic activity was due to pore formation. They then concluded that the 
minimum length for the peptide to span the membrane was 20 amino acids long. This, 
however, was soon proven false.
The authors continued to do research on the CA(1-13)M(1-13) peptide. By 
deleting amino acids from the hydrophobic melittin like region of the hybrid, they 
showed that even 15 amino acid peptide hybrids have lytic activity26. This finding 
caused a revision of the theory of pore formation as the mechanism of action in the 
peptide. It is interesting to note the CD studies done on these peptides. Merrifield 
showed that the peptides that were 18 and 20 amino acids long contained some 0- 
sheeting in 4-12% HFIP with a plateau of 50% helicity at 16-20% HTTP. The small 
peptides were observed to have a high a-helix content at only 12% HFIP. This was 
attributed to the absence of the Gly-De-Gly-Ala which disrupts the helix continuity25.
With these findings, the authors decided that pore formation may be 
accomplished by noncovalent dimerization of the peptides to span the membrane or 
through a 3io-helix formation25.
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Table 1.4.1: Lytic Activity of Parent Peptides and Peptide Hybrids in pM CA, 
CecropinA; M, Melittin; EC, Escherichia coir, PA, Pseudomonas aeruginosa; SA,
Staphylococcus aureus; SRC, sheep rec blood cells
Parent Peptides EC PA SA SRC
Cecropin A (1-37) 0.2 4 >200 >200
Melittin (1-26) 0.8 0.2 0.2 4-8
Hybrid Peptides
CA(1-24)M(1-13) 0.3 0.5 6 >200
CA(1-13)M(1-13) 0.5 0.7 2 >200
CA(25-37)M(1-13) 200 20 >300 >300
M(1-13)CA(1-13) 1 0.3 5 80
M(16-26)CA(1-13) 0.7 0.7 10 >200
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2.1 De Novo Peptide design
Studies have shown that sequence homology is not prerequisite for biological 
activity as long as the peptide remains amphipathic and is of sufficient length 21. 
Simplified analogs of natural peptides that retain or enhance helix amphipathicity and 
“minimalist” de novo designed amphipathic helix peptides have lytic activity28. The 
purpose of the research accomplished was to design antimicrobial peptides using a 
“minimalist” approach. The goal was to incorporate features found in nature with 
recent advances in de novo design to form peptides that were both antimicrobial and 
gave information concerning the mechanism of interaction of the peptides. The design 
of the peptides were based on the “pore” theory of their mechanism in which the lytic 
activity of the peptides occurred due to the formation of a pore across the membrane 
which depolarizes the membrane and causes subsequent lysing. In order for this to 
occur, in our design structure, one had to make the peptides so that they possessed the 
possibility to aggregate in a certain fashion. Hence the peptides had to be amphipathic 
when in an a-helical structure and leucines were used in the hydrophobic region to 
ensure that aggregation could occur.
An aspect of the design actively explored was the role of the hydrophilic face of 
the peptides. This was based on the idea that the degree arc of the hydrophilic face 
could affect how the peptides would aggregate in a membrane. By having a large 
degree arc, one would expect a larger pore to form while having a smaller degree arc, 
one would have a smaller pore form. If the actual size of the pore could not be affected, 
then the ease of aggregation of the pore could be affected by the amount of nonpolar 
moiety present in the system.
20
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Another aspect of the antimicrobial peptides was explored concerning the idea of 
a leucine zipper. Leucine zippers would be used to facilitate the aggregation of the 
peptides in aqueous environment. With the peptides aggregated into discrete packages 
in aqueous environment, one could think of this as a form of delivering the peptides to 
cells in “packages”. After initial binding to the cell membrane, the peptide tetramers 
would then quickly rearrange to a pore formation and lyse the cell. Hence, if the pore 
model is correct, the peptides would act as their own drug delivery system and less 
peptide would be needed in order to facilitate a lytic and thus antimicrobial response.
Finally, the peptides were designed in a minimalistic fashion so that, if their use 
as a drug was possible, the peptides would be easy to mass produce through solution 
phase synthesis. The peptides were designed as heptad repeats. Heptad repeats have the 
ability to form descreet amphipathic units while making them easier to produce with 
solution phase chemistry. Therefore we designed putative lytic peptides consisting of 
heptad repeats by subdividing the heptad into two identical trimers and an additional 
residue. To keep the polar and nonpolar faces approximately the same size there are 
two possibilities: design trimers made from two nonpolar residues, N, and one
positively charged residue, P, with an additional positively charged residue, P; or 
trimers made from one N, two Ps and an additional N. There are nine possible and eight 
unique combinations of heptads for each of these possibilities. The heptads composed 
with trimers N,N and P with a P are: (PNN)(PNN)P, (PNN)P(PNN), P(PNN)(PNN), 
(NNP)(NNP)P, (NNP)P(NNP), (NPN)(NPN)P, (NPN)P(NPN), and P(NPN)(NPN). 
The latter three heptads are not amphipathic in a-helical conformations and so were not 
considered further. The peptides that were designed and synthesized can be generalized
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as (PNN)(PNN)P and (NNP)P(NNP). This design approach generates a large number of 
structurally related peptides that differ only in the sequence or that have similar 
sequences with single amino acid residue replacements at several related sites in a 
peptide. Figure 2,1.1 shows the two distinct amphipathic peptides generated by the 
above sequences. These peptide designs encompass all the aspects that was desired 
which were to be minimalistic and have distinct parameters. The change in the 
sequence of the designed heptad changed the polar face of the peptdes. This was a 
source of experimentation to see if the degree-arc of polar face would change the 
biological activity of the peptides. Finally, the face of the nonpolar aspect of the 
molecule provided a site for possible aggregation.
2.2 Specific Peptide Design
The amino acids incorporated in the P and N of the above de novo design system 
were leucines, lysines and alanines. Leucines were used to provide a possible site for 
aggregation of the peptides. The lysines provide a positively charged amino acid which 
would be easily incorporated into a peptide and would be easily used on a solid phase 
peptide synthesis. Finally, the alanines were incorporated because of their ability to 
promote a-helicity.
The first peptide designed consisted of a heptad of 
(Lys,Leu,Ala,Lys,Leu,Ala,Lys) repeated three times. It was designed to be a 21 residue 
peptide in order to assure that it would span a membrane and obtain an a-helical 
structure under appropriate conditions.
By definition, a leucine zipper can occur when leucines are placed in every 
seventh position on a peptide chain. Following this rule, the peptides designed will be
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(PNNPNNP) (PNNPPNN)
Figure 2.1.1: Two amphipathic structures generated by the heptad sequences. The left 
figure represents a 160° polar face while the right figure represents a 180° polar face
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capable of forming leucine zippers. The primary leucine zipper has three leucine amino 
acids spaced so that they will have the ability to aggregate easily. When a peptide 
assumes an a-helical conformation, it is usually the core of the peptide that will be most 
helical, while the ends of the peptide will have more random coil character. Therefore, 
the leucines in the core of the peptide will form a more stable aggregated state and are 
thus defined as the primary positions. The other leucines, called the secondary system, 
are four amino acids away from the primary system and help to stabilize the leucine 
zipper by providing additional hydrophobic character. Figure 2.2.2 represents the 
Edmundson wheel of this particular peptide. This peptide shows a 180° polar face with a 
possible leucine aggregation site.
Another peptide was designed to determine whether the peptide activity was 
sequence dependent. The sequence is (Lys,Ala,Leu,Lys,Ala,Leu,Lys)3 and is very 
similar to the first sequence presented in this section, another. Consequently the leucine 
zippers in the primary state will be closer to the lysine polar face of the peptide. The 
peptide with a 180° polar face is shown figure 2.2.3.
Finally another design consisted of the heptad sequence of 
(Lys,LeuvAla,Lys,Lys,Leu,Ala). This demonstrates that by merely changing the 
sequence of the amino acids, the peptide can have a different polar face in the a-helical 
structure. In this case, the leucine zipper in the primaiy position are still adjacent to the 
lysine polar face of the peptide. The peptide has a 160° polar face and figure 2.2.4 
shows the Edmundson helical wheel of the peptide.
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Figure 2.2.2: Edmundson wheel of (Lys,LeurAla,Lys,Leu,Ala,Lysj
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To conclude, the peptides were designed to show how changes in the sequence 
homology of the peptides changes some basic characteristics. All peptides designed in 
this section have common characteristics. First, they all are designed in the minimalist 
fashion with the same amino acids used in each peptide and all amphipathic when in an 
a-helical conformation. They also have the ability to aggregate in a descreet fashion 
using a phenomena called a leucine zipper. The difference in these peptides result from 
changes in the sequence homology of the peptides. Due to the changes in the sequence, 
two peptides have a 180° polar face while the third has a 160° polar face.
2.3 Results and Discussion
2.3.1 Solid Phase Peptide Synthesis
The peptides were all synthesized using a Milligen 9050 peptide synthesizer. As 
opposed to solution phase peptide synthesis, which couples dipeptides and tripeptides 
into larger ones, solid phase peptide synthesis couples individual amino acids 
sequentially in order to form the larger peptide.
Solid phase peptide synthesis uses a solid phase support which is covalently 
attached to the first amino acid. This anchors the first amino acid as the others are 
coupled to it sequentially. In this case, polystyrene beads with a polyethylene glycol 
chain, known as PAL-PEG-PS resin, was used as the solid phase support. The first 
amino acid is coupled to the resin via an amide link. The amino acids which follow are 
protected amino acids. The amino acids can have a variety of different protecting 
groups associated with them. In this methodology, the a-amine on the amino acids were
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1° Positions
Figure 2.2.3: Edmundson wheel o f  (Lys,Ala,Leu,Lys,Ala,Leu,Lys3
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Figure 2.2.4: Edmundson wheel of (Lys,Lue,Ala,Lys,Lys,Leu,Alaj
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protected using fluorenylmethoxycarbonyl (FMOC) while the 8-amine, in the case of the 
lysine, was protected with tert-butyloxycarbonyl (t-BOC). Two separate protecting 
groups are used because each protecting group is removed under different conditions, 
amines protected by FMOC are removed by a base, namely 20% piperidine, while the 
amines protected by t-BOC are removed by trifluoroacetic acid. These are called 
orthogonal protecting groups. By using this method, it is possible to deprotect the ex­
amine while still leaving the 8-amine protected. Finally, the carboxy portion of the 
amino acid is activated as a pentafluorophenol (Opf) ester.
The sequence of synthesis is as follows. The first amino acid is placed on the 
Pal-Peg-PS resin via an amide bond. The linked amino acid is then deprotected by a 
piperidine wash and the next amino acid is linked to it. This cycle is repeated until the 
desired peptide is made. After the peptide is made, the peptide is cleaved off the resin 
using TFA. The TFA also deprotects the t-BOC which protected the e-amine of the 
lysines. The peptide was purified by two separate methods. Originally the peptides 
were deprotected using a cleavage cocktail called Reagent B (8.8 mL triflouroacetic 
acid, 0.5 mL phenol, 0.5 mL water, 0.2 mL of triisopropylsilane). After stirring, the 
peptide was precipitated out of the cocktail by slowly pouring the peptide/cocktail 
solution into cold diethyl ether. The purified peptide was centrifuged into a pellet and 
allowed to dry. The peptide was dissolved in 20% acetic acid and passed through a 
Sephadex G-15 column to remove any residue of the cleavage cocktail and any very 
small peptides.
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Another method which was employed to purify the peptide was to directly 
dissolve the peptide/cleavage cocktail in 20% acetic acid and extract the solution in 
diethyl ether. The 20% acetic acid solution is frozen and lyophilized. The purpose of 
the diethyl ether extraction was to remove any of the nonpolar organics from the 
cleavage cocktail. This method also eliminated the need to pass the peptide through a 
Sephadex G-15 column. Both methods were employed during the synthesis phase of the 
research and worked equally well.
Due to the nature of solid phase synthesis, if an individual peptide was not 
successfully deprotected, then there could be failed coupling of the next amino acid. 
These were separated using RP-HPLC and all three peptides were purified using a RP- 
HPLC with a C-4 column. The mobile phase was a gradient consisting of water and 
acetonitrile. Both mobile phases had 0.5% TFA added to insure no bacterial growth and 
to buffer the solution. Once the conditions of purification were determined and the 
retention times were noted, a large amount of peptide, approximately 30 mg, was 
purified using a semi-preparatory C-4 column. A fraction of the purified peptide was 
rechecked using a C-18 analytical column. Plasma desorption mass spectroscopy was 
performed to determine if  the correct peptide was synthesized.
2.3.2 CD Measurements
A CD study was performed on the peptides to determine the structure as a 
function of concentration. This study did not use any salt, pH changes, or SDS micelles 
or vesicles to effect the formation of secondary structure. The study was conducted on 
the peptides to determine if the influence of the nonpolar portions of the amphipathic a- 
helix would enforce the a-helix by overcoming the repulsive forces of the charged
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amino acids on the peptides. If this was indeed the case and shows how the change in 
the sequence homology effects helix formation in the peptide.
Of the three peptides, (LySjAlajLeuXysAlaJ^eu^Lys^ gave the smoothest 
transition from a random coil to an a-helical shape. The a-helical CD spectrum is 
characterized by m in im a  at 208 and 222 nm while random coil has an m in im a  at around 
200. If a peptide is going from a random coil to an a-helical secondary structure, then 
all the CDs of this transition will pass through one point when layed on top of one 
another. This is called the isodichroic point and is shown in figure 2.3.1.
CD raw data is reported in millidegrees, m e a n in g  the degree the polarized light 
is shifted after it interacts with the peptide. In order to facilitate interpretation, the data 
is converted to molar ellipticity. This number represents the change in the degree of 
polarized light per mol of peptide residue. Molar ellipticity is usually calculated at 
222nm wavelength of light. This is done using the following formula:
[0 ]222= 100* (milidegreesl^
1000 * C * L
Where: C= concentration of peptide per residue (Mol)
L= Pathlength of the cell (cm)
After molar ellipticity is determined, % a-helicity for each peptide is determined 
using the following formula:
% a-helicity = 100* ( 161777 + 3000)
33000
With the above formulas, a table 2.3.2 is generated showing the different molar 
ellipticities and % a-helicities for each peptide studied.
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Figure 2.3.1: CD spectra of (Lys,Ala,Leu,Lys,Ala,Leu,Lys3
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Both (LysvLeuvA.la,LysJLys,LeaAla)3 and (Lys,LeuvAiaXysXeuvA.la,Lys)3 had 
similar transitions until the peptide concentration approached log 0.9 to 1.0. The peptide 
(Lys*AJaXeu,Lys,AlaJLeuJLys)3 also had the highest molar ellipticity of -24,887.26 at a 
log of 1.113 (12.97 mM). The peptide (Lys,LeuAla,Lys,Leu,Ala,Lys)3 has a molar 
ellipticity of -20,101.74 at a log of 1.063 (11.56 mM) while
(LysJJeuAla,Lys,LysJLeurAla)3 demonstrated the least propensity of aggregation with a 
molar ellipticity of -14,249.65 at a log of 1.15 (14.125 mM). Figures 2.3.3 and 2.3.4 
represent the CD spectra of (Lys,LeurAia,Lys,Lys,Leu,Ala)3 and 
(Lys,Leu,Ala,Lys,Leu,Ala,Lys)3. Figure 2.3.5 represents a comparison of the molar 
ellipticity vs. the log of the concentration of the three peptides.
The two peptides which demonstrated the greatest difference in propensity for a- 
helicity are (Lys,Leu,Ala,Lys,Lys,Leu,Ala)3, and (Lys,Leu,Ala,Lys,Lys,Leu,Ala)3. It is 
interesting to note that by merely changing the sequence of the amino acids, the 
propensity for a-helicity is dramatically changed. The explanation for this lies in how 
the peptides become a-helical. When a peptide is said to be in an a-helical 
comformation, this doesn’t mean that all amino acids are participating equally in the a- 
helix. In fact, as demonstrated by melittin, the ends o f the peptide still stay in a random 
coil conformation. a-Helicity does not actually start until the third residue of the 
peptide. The peptide (Lys,Ala,Leu,Lys,AlaXeu,Lys)3 has the highest propensity for 
aggregation due to the primary leucine zipper. As shown on figure 2.2.3, the primary 
leucine zipper for this peptide starts are on residues 3, 10 and 17. Therefore all o f the 
leucine amino acids are within the a-helical portion of the peptide and can equally
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Table 2.3.1: Relative Molar ellipticities and % a-helicities for 
(KALKALKfc, (KLAKKLAb, and (KLAKLAK)?
(KALKALK)3
Log [Peptides] mM Molar Ellipticity % a-Helicity
0.3784 1957.163 15.022
0.5545 2426.919 16.445
0.6794 5899.582 26.968
0.7763 8584.43 35.104
0.8585 13500.99 50.003
0.9557 16674.05 59.618
0.9836 21367.48 73.841
1.035 23117.42 79.144
1.081 24700.6 83.507
1.113 24887.26 84.507
Log [Peptides] mM
0.40926
0.58535
0.7103
0.80787
0.9212
0.98399
1.0120
1.0630
(KLAKKLA)s
Molar Ellipticity
954.4222
4687.674
7427.718
7939.197
13121.68
14293.2
16749.12
20101.74
% a-Helicity
11.9831
23.296
31.599
33.149
48.8536
52.404
59.8458
70.0052
(KLAKLAK>3
Log [Peptide] mM Molar Ellipticity % a-Helicity
0.449 1689.359 14.210
0.625 2873.4 17.798
0.769 5019.697 24.302
0.849 5570.235 25.970
1.025 12088.52 45.723
1.104 14171.35 52.034
1.150 14249.65 52.272
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Figure 2.3.4 Log [Peptide] vs. Molar Ellipticity of all the peptides
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participate in the aggregation of the peptide. In contrast, the primary leucine zipper for 
(Lys,Lei^Ala,Lys,LeuvAJa,Lys)3, the leucines for the primary zipper are located on 
residues 2, 9, 16. The leucine on residue number 2 is not in an a-helix conformation 
and therefore does not participate in a leucine zipper. The peptide 
(Lys,LeivYla,Lys,Lys,LeuA.la)3 also has the primary leucine zipper located on the 2, 9 
and 16 residue. The greater tenacity of this peptide for aggregation is due to the 160° 
polar face. Any type of aggregation is helped with nonpolar residues. The greater the 
face of nonpolar residues, the greater the propensity for nonpolar-nonpolar interactions. 
2.3.3 Materials and Methods of Bioassay
All bioassays were done by Martha Juban. Purified peptides were assayed for lytic 
activity against ATCC strains of Escherichia coli 25922, Pseudomonas aeruginosa 
27853 and Staphylcoccus aureus 29213. Minimum inhibitory concentrations were 
determined by the broth microdilution method outlined for aerobic bacteria in NCCLS 
Document M7-A2, second edition.
Peptide solutions were prepared as a serial 2:1 dilutions from a 512 |ig/mL to 2 
pg/mL. Bacterial cultures were grown to mid-log phase in nutrient broth and visually
standardized to a 0.5 McFarland turbidity tube before dilution. 5 x 10^ cells in 50 pL of 
broth were added to an equal volume of peptide solution in sterile wells, and incubated 
overnight. The MIC is the lowest concentration of peptide that completely inhibits 
growth of the organism as detected by the unaided eye.
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2.4 Experimental
2.4.1 General Methods
The peptides were synthesized on a Milligen 9050 peptide synthesizer using 
orthogonally protected amino acids. The a  amines were protected using FMOC and the 
e-amines on the lysines were protected with t-BOC. The carboxylate ends of the 
amino acids were activated as an OPfp ester. The resin used was PAL-PEG-PS and all 
amino acids were weighed to have a 4 fold excess compared to the resin substitution 
level. HPLC was conducted on a Waters 600E instrument. The analytical and prep 
methods used a Waters C4 cartridge column while the prep fractions were checked 
using a Vyadac C-18 column. The mobile phase was a gradient of double distilled 
water and acetonitrile. CD concentration studies were carried out on a Aviv Model 
62DS CD spectrometer. The pathlengths of the cells varied from 0.001 cm at high 
concentration to 0.01 cm at lower concentrations. All concentration studies were 
carried out using 2.5mM potassium phosphate buffer pH= 7.45.
2.4.2 Solid Phase Peptide Synthesis
The procedure for the synthesis of a peptide via solid phase peptide synthesizer 
follows a repetitive scheme. After the PAL-PEG resin is placed in a column, there is an 
initial washing of the resin using DMF at 5mL/ min which cleans the resin/amino acid. 
This is followed by a piperidine wash for lOmin at 5ml/min. Since piperidine is a base, 
the purpose of it is to remove the FMOC protecting group of the a-amine on the amino 
acid anchored on the resin. After this step, the resin/peptide is washed again with DMF 
for 12 min (at 5mL/min). This needs to be done in order to insure that residual 
piperidine is removed. While the resin is being washed, the next amino acid is being
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dissolved in DMF and 1-hydroxybenzotriazole (HOBT). The HOBT improves coupling 
yields. The amino acid, after being dissolved in the DMF/HOBT, is delivered to the 
resin where it is recycled through the resin for 1 hour. This is followed by an 8 minute 
DMF wash to remove the excess amino acid present in the system. The above is 
repeated until the peptide has been completed. After the final amino acid is placed on 
the peptide, there is a 12 minute DMF wash at 5 mL/min and a 15 min DCM wash. At 
this point the peptide/resin combination is taken off of the synthesizer and is manually 
washed with MeOH in order to shrink the resin and it is filtered and dried in a high 
vacuum desicator. After drying the peptide is cleaved using reagent B. Reagent B is 
made by combining 8.8 mL trifluoroacetic acid, 0.5 mL phenol, 0.5 mL water, 0.2 mL 
of triisopropylsilane while bubbling Ar through the system. This is added to the 
peptide/resin and stirred for 4 hours and the mixture was filtered to remove the peptide 
from the resin. Again two methods were used to purify the peptide. In the first 
method, the solution containing the peptide was dropped into cold diethyl ether where it 
precipitated as a white solid. The diethyl ether is then placed into Corex tubes and 
centrifuged at 7000 rpm for 20 minutes at 20°C in order to concentrate the peptide into a 
pellet. The diethyl ether is poured off and allowed to evaporate. The crude peptide was 
then dried overnight in a vacuum desicator. After drying, the peptide was dissolved in 
0.1 M acetic acid and ran through a Sephadex G-15 column in 100 mg portions. This 
removes residual organic molecules as well as small peptides which represent failed 
sequences. The second method involves dissolving the peptide solution in 20% acetic 
acid and extraction with diethyl ether. The peptide, in the aqueous solution, is frozen 
and lyophilized. The cmde peptide is then further purified using HPLC.
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2.4.3 CD Studies
The CD instrument was purged with liquid nitrogen blow-off for 30 minutes 
before starting. A series of solutions were made with concentrations varying from 40 
mg/mL to 8 mg/mL. All solutions were prepared from a stock solution of -40 mg/mL 
(this was subsequently corrected via amino acid analysis) using 2.5 mM sodium 
phosphate buffer at pH=7.3. The pH of the buffered solution was subsequently checked 
after the addition of the peptide. A CD spectrum was taken from 225 nm to 190 nm at 
1 second per point sampling at every 0.5 nm with a bandwidth of 0.7 nm. Two scans of 
each solution were taken. The resultant milidegrees at 220 nm were converted to molar 
ellipticity and graphed as a function of log of concentration of peptide in mM.
2.5 Conclusion:
This work demonstrates not only the importance of leucine zippers in 
aggregation, but also the importance of the placement of the leucine zippers in the a- 
helical wheel. If not all three leucines are within the a-helical region of the peptide, 
they will not be able to complete a proper leucine zipper. The result will be a peptide 
which will have a decreased molar ellipticity due to a decrease in the stabilizing force of 
the aggregation state which holds the peptide in an a-helical state.
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3.1 Uses of Pyrenylalanine
The excited state of pyrene has the unique property of having a high quantum 
yield and a long lifetime. It also forms an excimer when two pyrenes are within 3 A 
from one another due to the overlapping of the n orbitals. Because of this, it has been 
used as a fluorescent probe. Since 1983, pyrenylalanine (figure 3.1.1) has been used to 
probe the formation and behavior of peptides and polymer.
Sisido synthesized block polymers of pyrenylalanine with blocks of benzyl 
glutamates in order to study the spectroscopic properties of the pyrenylalanines.29 
Poly(y-benzyl dl-glutamate) solubilized the long pyrenylalanine polymer and was 
studied using CD and fluorescence spectroscopy. Sisido observed tentative evidence 
that the pyrenyl portion of the peptides arranged itself in a sandwich-like configuration. 
Homochiral polymers showed reduced excimer formation while racemic polymer had 
predominant excimer formation. He concluded that descreet arrangement of the peptides 
reduced excimer formation. Sisido continued his work by doing a more detailed study 
of the block copolymer of glutamate and pyrene. 30 Using advanced techniques, he 
isolated the components of fluorescence to show where the excimer formation arises 
from the random coil and from more ordered systems.
Pyrenylalanines have probed solvent affects on dipeptides. De Schryver 
synthesized w-acetyl-bis(pyrenylalanine)-methylester (both the erythro and threo 
compounds) in order to determine how solvent effects the arrangement of random coiled 
peptides. 31 He concluded that hydrogen donating solvents reduce the partial double 
bond character of the peptide by hydrogen bridging with the solvent making the 
dipeptides more structured. Hydrogen accepting solvents shifted the dipeptides to a
42
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Figure 3.1.1: Pyrenylalanine
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more random coil conformation by decreasing intramolecular hydrogen bonding. De 
Schryver continued his work using both stationary and transient fluorescence techniques 
to determine how dipeptides behaved in systems. 32 He concluded that the dipeptides 
are stabilized through intramolecular hydrogen bond formation in the presence of 
solvents which cannot form hydrogen bonds.
Pyrenylalanine has been used to investigate opiate receptors. In the mid ‘80s, 
Costa published a series of papers in which pyrenylalanine was incorporated into the 4 
or 5 position in [D-Ala2, D-Leu5]enkephalins (heretofore known as DADLE) and its 
methyl ester. 33 The incorporation of pyrenylalanine made the modified DADLE five 
times more selective for the 5-receptor. When pyrenylalanine replaced an essential Tyr1 
in an enkephalin, the result showed the pyrenylalanine enkephalin bound to an opiate 
receptor to a point of inhibiting the Tyr 1-containing enkephalin. It is also noted that the 
methyl ester derivative bound to the p. receptor than to the 5 receptor 24 fold more 
strongly while the C-terminal free analogue of the pyrene enkephalin analogue showed 
preference for a 5 receptor. Incorporation of two pyrenylalanines into an enkephalin 
analogue in the 1 and 4 or 5 position made the peptide unable to interact with the opiate 
receptor.34
Another aspect of pyrenylalanine investigated involved the idea of photoinduced 
electron transfer in a-helical backbones.35 In one paper, p-dimethylanilino acted as an 
electron donor while pyrenylalanine acted as a photsensitizer with an alanine separating 
the two groups and coupled to a copolymer of y-benyl-l-glutamate. The peptide showed 
electron transfer between the donor and the pyrenylalanine.
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Other uses of pyrenylalanine involved the incorporation of it into chiral bilayer 
membranes that had the property of going from a gel phase to a liquid crystalline phase 
at 35.2°C.36 The authors reported that, while in a gel phase the pyrenyl groups arranged 
in such a way to prevent excimer formation while in the pyrenyl groups randomly 
ordered in the liquid crystal phase.
Sannamu Lee incorporated pyrenylalanine into an amphipathic/antimicrobial 
peptide to gain insight into the action of peptides on lipid bilayers. 37 The 
photophysical results of the peptides interactions on bilayers appeared in a subsequent 
paper.38 The amphipathic peptide contained a basic sequence of four amino acids; 
namely, -L-Leu-L-Ala-L-Arg-L-Leu- in a four quadrad repeat called A4 . Three different 
peptides incorporated the pyrenylalanine in the 5th, 7th, and 9th position while one 
peptide incorporated two pyrenylalanines in the 5th and 9th position. Experiments on 
these peptides included CD, fluorescent binding studies with DPPC and the authors 
reported that the labeled peptides existed as a monomer in the liposome layer while as 
an oligomer in an aqueous layer. The authors also did a quenching study of a 
tryptophan labeled peptide in a DPPC bilayer and found that iodine did not quench the 
tryptophan fluorescence. This led the authors to believe that the tryptophan embedded 
into the nonpolar lipid bilayer while the rest of the peptide lies on the surface of the 
bilayer. They further concluded that the nonpolar portion of the amphipathic peptide 
interacted with the lipid bilayer. The authors also observed via CD, that the 
introduction o f the fluorescent side chains in the nonpolar region of the peptide could 
induce peptide-peptide interactions. This paper clearly demonstrated the use of 
pyrenylalanine in investigating lipid-peptide and peptide-peptide interaction.
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Pyrenylalanine has been used to explore the interaction of two amphipathic a- 
helical peptides anchored by a bipyridyl group.39 The peptides incorporated 
pyrenylalanine in the nonpolar region at the interface between the Leu and Ala. 
Circular dichroism monitored the interaction of the peptides in both aqueous and 
MeOH solvents. The authors noted that in an a-helical configuration, the pyrene groups 
aligned themselves between the two a-helical peptides. MeOH induced a random coil 
configuration and the pyrenes did not align themselves. A subsequent paper reported 
further CD and fluorescent data appeared in another paper. 40 Here the authors give 
evidence of excimer formation under aqueous conditions. The authors also did studies 
of the denaturation of the covalently attached a-helical bundles using MeOH, heat and 
guanidine HC1. The covalently bundled peptides exhibited standard denaturation 
characteristics as evidence through both CD and fluorescent studies. As the peptides 
became more random coil, an absence of excimer formation occurred.
The use of pyrenylalanine as a fluorescent probe in covalently attached a-helical 
bundles extended to a 4 covalently attached a-helical bundles. 41 This paper reported 
both fluorescence and CD spectra. The result showed that the pyrenylalanine, properly 
placed in the hydrophobic region of the peptide, resulted in excimer formation in 
aqueous environments. Aqueous environments do promote a-helical structures. Using 
MeOH as a solvent resulted in little if any excimer formation. The authors stated that 
the peptide most likely formed a random coil in an MeOH environment and therefore 
little if any excimer occurred. The authors reported no other evidence that the 4 
covalently attached a-helical bundle folded into a bundle structure.
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Finally, pyrene explored the nature of leucine zippers in an amphipathic peptide. 
42 Garcia-Echeverria used pyrenebutyric acid to label a peptide within its leucine zipper 
region. CD and fluorescence experiments showed the peptide formed a dimer in 
aqueous conditions. The fluorescence occurred only if the peptide arranged itself in a 
parallel dimer formation.
In conclusion the literature clearly shows the usefulness of pyrenylalanine and 
pyrene products. Through various techniques which depend on the unique fluorescent 
properties o f pyrene, many aspects of the peptides aggregation and structure comes to 
light.
3.2 Methods for the synthesis of Pyrenylalanine
Various methods have been used to synthesize pyrenylalanine. One of the first 
involved the formation of an oxalazone with hippuric acid and pyrene carboxaldehyde. 
This was then hydrogenated and oxidized using phosphorous. 31 This was a racemic 
mixture though and consequently they were used in this fashion. Figure 3.2.1 illustrates 
the method for the synthesis of pyrenylalanine.
The most common method for the synthesis of pyrenylalanine is a variation of 
the above. In this case, the pyrene oxalazone is ring opened using sodium ethoxide and 
then resolved using (-)-l-phenylethylamine. The result is enantiomercially pure 
pyrenylalanine. 30 The number of steps in this procedure is six and because the product 
has to be resolved, the yield on this set of reactions is poor. Figure 3.2.2 illustrates the 
experimental procedure of this reaction.
Another method that has been used for the synthesis of pyrenylalanine involve 
creating a template that would only allow the hydrogenation of the precursor
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enantionselectively. This molecule first involved the formation of a cyclic dipeptide of 
glycine and alanine. 34 Chirality of the molecule is introduced with the alanine. The 
methyl group of the alanine allows for only one face of the pyrene to associate with the 
palladium. Because of this, only one side of the precursor will be hydrogenated making 
this enantioselective. Figure 3.2.3 illustrates this reaction set.
Finally, a more interesting method has also been found to produce 
pyrenylalanine. This involves the use of a acylase. acetyl-DL-Pyrenylalanine was 
produced using any method of choice. After this Aspergillus acylase was used to 
deacetylate only the L-pyrenylalanine causing it to precipitate out of solution. This was 
then collected and used in the experimentation. 40
3.3 Synthesis of Pyrenylalanine
The synthesis of pyrenylalanine gave us an opportunity to explore the area of 
glycine templates. Glycine templates are molecules which have a chiral substituent that 
cause an alkylation to the template to occur enantioselectiveiy. This method offers 
superior enantioselectiveiy compared to methods which rely on resolution or one in 
which hydrogenation is directed enantioselectivty. After alkylation, the removal of the 
enantiomeric directing group is removed and the product is isolated. One such glycine 
templates is (2R,3S)-(-)-6-oxo-l,4-morphiline-carboxylate or William’s template (see 
figure 3.3.1). The alkylation is directed enantioselectivly by the two chiral phenyl 
substituents. Once deprotonated, the glycine template will attack an alkyl halide via a 
backside attack shown in figure 3.3.2.
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Figure 3.2.1: Synthesis of racemic pyrenylalanine
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Figure 3.2.2: Synthesis of pyrenylalanine with resolution
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Figure 3.2.3: Synthesis of Pyrenylalanine via enantioselective hydrogenation
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Attempted synthesis of pyrenylalanine was a modification of the procedure 
presented in the literature.[William’s, 1990 #93] It involved the following steps. 
Alkylation of 1-bromomethylpyrene with (2R,3 S)-(-)-6-oxo-1,4-morphiline-carboxyIate 
was accomplished by first converting the template to the enolate using Na 
bistrimethylsylyl amide and then reacting with 1-bromomethylpyrene. The Boc-group 
was removed with the use of trimethylsilyliodine in an inert atmosphere. The reaction 
was judged over in about 30minutes via TLC (mobile phase: 50% Hexane, 30% 
Chloroform 20% Ethyl Acetate). The template was ring opened using 6M HC1. Finally 
the phenyl rings were to be removed using sodium periodate through oxidation of the 
phenyl rings to benzaldehyde. Unfortunately, the final step of this reaction did not 
occur possibility due to the insolubility of the starting material. The solvent conditions 
for this reaction is THF/H2O adjusted to a pH of 3. As the reaction continued, the 
starting material would precipitate. Figure 3.3.3 illustrates the reaction sequence using 
William’s glycine template.
Another template attempted involved a template first synthesized by Seebach. 43 
This uses the glycine template l-benzyl-2-r-butyl-3-methyl-4-imidazolidinones (see 
figure 3.3.4). In this case, the enantioselectivity of the molecule is controlled by the 
chiral terf-butyl group. This molecule has the additional advantage of, when the 
alkylation occurs, the enantioselectivity can be checked by NOESY NMR due to the 
interaction of the a-proton with the protons on the terf-butyl group which is shown in 
figure 3.3.5. After alkylation, the glycine template was hydrolized to remove the tert- 
butyl group and form the amino acid. Under various conditions attempted, this did not 
occur. Figure 3.3.6 shows the reaction sequence using Seebach’s template.
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Figure 3.3.1: William’s glycine template
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Figure 3.3.2: Alkylation backside attack via glycine template
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The failure of all these reactions did not occur in the alkylation, but in the final 
step of the reaction involving the final formation of the amino acid. It was in the 
hydrolysis step that failed in these sequences. The reaction sequence that did work 
used the glycine template invented by O’Donnel. In this template, the hydrolysis step 
was very facile. Though the reaction does not go enantioselectiveiy, the product was 
finally synthesized. Figure 3.3.7 illustrates the reaction sequence for the formation of 
pyrenylalanine.
3.4 Incorporation of Pyrenylalanine into a peptide
The peptide chosen to incorporated the pyrenylalanine was H-(Lys,Leu,Ala, 
Lys,Lys,LeurAia)3-NH2. The Alanine in the 14th position was replaced with the 
pyrenylalanine. The synthesis of the peptide containing the pyrenylalanine was 
accomplished by solid phase peptide synthesis as described in the previous chapter.
Purification of the peptide via HPLC was done under similar conditions as 
described in the previous chapter. However, since the pyrenylalanine amino acid was 
racemic, the peptide had to be purified enantiomercially. In order to explain how the 
peptide was purified enantiomercially, one must understand how a C-4 column works. 
The nonpolar regions of the peptide bind to the stationary phase of the column upon 
initial conditions of the mobile phase which is, in this case 90:10 HiOtCHsCN. As the 
nonpolar portion of the mobile phase increases, the peptide will then disassociate with 
the stationary phase allowing it to come out purified. Since different peptides are 
unique, the percentage of polar/nonpolar mobile phase in which the peptide comes off is 
also unique. Therefore peptides which contain amino acids that did not couple, and 
therefore shorter than there parent peptide, will come off at a different time, called the
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Figure 3.3.3: Attempted Synthesis of Pyrenylalanine using William’s glycine template
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Figure 3.3.4: Seebach’s glycine template
CH
Figure 3.3.5: Alkylated Seebach’s glycine template demonstrating how NOESY 
interactions are used to check the enantioselectivity of the reaction
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Figure 3.3.6: Attempted synthesis of Pyrenylalanine using Seebach’s Glycine template
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Figure 3.3.7: Synthesis of Pyrenylalanine via O’Donnel’s glycine template
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retention time, than the completed peptide. What is critical to this system is the actual 
binding of the peptide to the column stationary phase. The mobile phase 90% H20/ 
10% Acetonitrile causes the peptide to assume an a-helical shape. In this particular 
case, the peptide synthesized is a mixture containing one with an L-pyrenylalanine and 
another with a D-pyrenylalanine. When these peptide are a-helical, the one containing 
the D-pyrenylalanine, is bent as compared to the one containing the L-pyenylalnine. 
This cause the peptide with the D-pyrenylalanine to have different binding efficiencies 
than the one with the L-Pyrenylalanine. Therefore the retention time of the D- 
pyrenylalanine containing peptide will be slightly less than the L-pyrenylalanine 
containing peptide. This fact was exploited in order to purify the peptides 
enantiomerically.
3.5 CD and Fluorescence studies of pyrene containing peptide
As the peptides form an a-helical shape, they will tend to aggregate. The 
question arised as to whether they aggregate parallel or antiparallel to one another. With 
a pyrenylalanine in the 14th position on the peptide, if the peptides aligned in an 
antiparallel fashion, then the pyrene may be in close enough proximity to cause the 
formation of excimer. If the peptides aggregated in an parallel fashion, the pyrenes 
would not be close enough to form an excimer thus showing no such evidence in the 
fluorescent studies. The peptide (Lys,LeurAla,Lys,Lys,Leu,Ala)3 was used as a model 
peptide in order to get the solvent conditions appropriate for the peptide containing the 
fluorescent probe. After incorporation of the fluorescent probe, an absorbance was 
taken in order to determine if the probe was within the structure and also to determine 
the concentration of the peptide in various experiments completed (see figure 3.5.1).
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The absorbance of the pyrene in the peptide is characteristic of other pyrene containing 
peptides noted in the literature.
All CD and fluorescent studies were completed in 2.5mM tris buffer. This was 
done due to a better behavior of peptides in Tris buffer as opposed to phosphate buffer. 
As stated, the CD’s of the peptides were done on with (LysJLeurAla,Lys,Lys,LeurAla)3 
acting as a model compound. The object of one of the experiments was to find the best 
solvent conditions for the peptides to exist in an a-helical shape. Figure 3.5.2 shows 
the CD of the fluorescently labeled peptide in 1M NaCl in tris buffer. The graph is 
reported in molar ellipticity. Using the formula discussed in the previous chapter, the 
helicity of the peptide is 81.49%. This affords a good helicity for the peptide to study 
the possible interactions of the pyrenes in an aggregated state.
Fluorescent study of the peptide was carried out on an SLM model fluorimeter 
utilizing magic angle. Again this was carried out in 2.5mM tris buffer with 1M NaCl at 
pH=7.42 using a 35 pL capillary ceil. A second study was also carried out in 2.5mM 
tris buffer without NaCl. Both spectra are shown as figures 3.5.3 and 3.5.4. The peptide 
is not in an a-helical state without the salt and at these concentrations. Because it is not 
in an a-helical state, it will not be aggregated in an ordered state. Therefore one can 
see if there is a difference in the fluorescence between an ordered stated and a 
nonordered state of peptides.
The fluorescent spectra represented here show the emission spectra when the 
peptide was excited at different wavelengths. A difference can clearly be seen between 
both spectra when the peptide was excited at 330 nm. In the system which contained 
the 1M NaCl, there is a definite tailing in the spectra while the system containing the no
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Figure 3.5.1: Absorbance spectra of labeled peptide
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Figure 3.5.2: CD spectra of labeled peptide
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Figure 3.5.3. Emission spectra of labeled peptide 1 M NaCl. ------, 315 nm excitation;
 , 330 nm excitation; , 345 nm excitation; 365 nm excitation; 400
nm excitation.
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Figure 3.5.4: Emission spectra of labeled peptide 0 M NaCl. ----- , 330 nm excitation;
 , 345 nm excitation; , 365 nm excitation; 400 nm excitation.
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NaCl there is no such tailing. Because it is being excited at 330 nm, which is 
considered a low wavelength with pyrene, this is indicative of a ground state emission. 
Usually in pyrene, a molecule is first excited and then an emission is observed. This 
excitation is seen when the molecule is excited at wavelengths higher than 365 nm.
3.6: Experimental
3.6.1: Synthesis o f  1-bromomethylpyrene
The synthesis of 1-bromomethylpyrene followed a procedure found in a paper 
by Akiyama with a slight modification.44 5.0 g (0.02 mol) of pyrenemethanol was 
dissolved in 100ml of dry dichloromethane, under Argon, and cooled to 0°C. To this 
solution was added 0.0908 mL (0.0112 mol) of pyridine. 1.76 mL (0.0187 mol) of 
PBr3 was dissolve in dry dichloromethane and added to the pyrenemethanol over a 
period of 20 minutes. The reaction was then allowed to go overnight. The reaction was 
then placed in a separatory funnel and cooled double distilled water was added. The 
organic layer was subsequently washed with water, aqueous sodium bicarbonate and 
water. The organic layer was then dried with sodium sulfate, filtered and rotovapped. 
The solid 1-bromomethylpyrene was collected as a yellow powder in an 85% yield; m.p. 
141°C; lit m.p. 131-133°C; 1HNMR(200Mhz, CDCl3) 5.25(s,2H) 8.00-8.57(m,9H).
3.6.2: Synthesis o f (3R,5R,6S)-4-(fert-ButoxycarbonyI)-2,3,5,6-tetrahydro-3-
pyrenyl-5,6-diphenyl-l,4-oxazin-2-one.
1.36 g (0.0075 mol) of sodium bis(trimethylsilyl)amide was dissolved in dry 
THF under Argon and cooled to -78°C using a dry ice/acetone. To this was added 
slowly in a dropwise fashion, 2.39 g (0.0068 mol) of (3R,5R,6S)-4-(tert-
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Butoxycarbonyl)-2,3,5,6-tetrahydro-5,6-diphenyl-l,4-oxazin-2-one dissolved in dry 
THF. After 20 minutes of stirring, 2.0 g (0.0068 mol) of bromomethylpyrene dissolved 
in dry THF was added dropwise to the above solution and was allowed to stir overnight. 
Double distilled water was added to the system in order to destroy excess base still 
present in the system. The product was extracted with diethyl ether and dried over 
anhydrous sodium sulfate. TLC (mobile phase: 50:30:20 Hexane/Chloroform/Ethyl 
Acetate) revealed two spots at Rf 0.7 and 0.85. The solvent was removed and the 
product was recrystallized in refluxing acetonitrile. yield 90%; !H NMR (200MHz, 
CDCl3) 1.04(s,9H) 3.54(d,lH) 3.92(d, 1H) 4.08(d, 1H) 4.41(d, 1H) 5.49(d, 1H) 
5.87(d,lH) 6.25(d 1H) 6.8-6.94 (m, 10H) 7.7-8.3(m, 9H)
3.6.3: Synthesis o f (3R,5R,6S)-2,3,5,6-tetrahydro-3-pyrenyI-5,6-diphenyI-l,4-
oxazin-2-one
This reaction follows closely the procedure published by Williams45 without 
modifications. 2.0 g (0.0035 mol) of (3R,5R,6S)-4-(tert-Butoxycarbonyl)-2,3,5,6- 
tetrahydro-3-pyrenyI-5,6-diphenyI-l,4-oxazin-2-one was dissolved in dry 
dichloromethane and stirred under argon. To this was added 1.72 g (0.0085 mol) of 
trimethylsilyl iodide and stirred for 30 minutes. The reaction was then quenched with 
15 mL of water and extracted with dichloromethane. The combined organic layers were 
washed with 1M sodium thiosulfate. The organic layers were then dried with anhydrous 
sodium sulfate and rotovapped. Yield 92%; lH NMR (200MHz, C D C I3) 3.77-3.87 (dd,
1H) 4.27-4.33(dd, 1H) 4.50-4.56(dd, 1H) 4.90(d, 1H) 5.29(dd, 1H) 6.8-7.25(m, 10H)
7.78-8.47 (m, 10H)
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3.6.4: Synthesis o f N-(l,2-dibenzyl-ethan-2-ol)-pyrenylalaiiine
This followed closely the procedure of Williams.45 1.5 g (0.0030 mol) of 
(3R,5R,6S)-2,3,5,6-tetrahydro-3-pyrenyl-5,6-diphenyl-l,4-oxazin-2-one was dissolved 
in a mixture of 25 mL of THF and 50 of 10% HC1 and allowed to stir overnight. This 
was then rotovapped under high vacuum. Yield 95%; lH NMR (200 MHz, DMF-cU)
2.78-2.95 (dd, 1H) 3.7-3.S (dd, 1H) 4.8(d, 1H) 6.86-7.18(m, 10H) 7.99-8.37 (m, 10H)
3.6.5: Attempted synthesis o f Pyrenylalanine
1.45 g (0.0028 mol) of N-(l,2-dibenzyl-ethan-2-ol)-pyrenylalanine was 
dissolved in 25mL of THF. 1.33 g (0.0062 mol) of sodium periodate was dissolved in 
45 mL double distilled water adjusted to pH=3 and added to the N-(l,2dibenzyl-ethan- 
2-ol)-pyrenylalanine solution. This was allowed to stir for three days. After this the 
flask had a white precipitate which NMR revealed to be starting material.
3.6.6: Synthesis o f  (2S,5R)-l-benzoyl-2-ter/-butyI-5-pyenyl-3-methyI-4-
imidazolidinone
1.3 mL of 1.5 M LDA was dissolved in THF and placed in a flask under argon and 
cooled to -78°C using an acetone/dry ice bath. 0.34 g (0.0013 mol) of (2S)-l-benzoyl- 
2-te/Y-butyl-3-methyl-4-imidazolidinone was dissolved in dry THF and slowly injected 
into the flask and allowed to stir for 20 minutes. 0.35 g (0.0012 mol) of 
bromomethylpyrene was dissolved in dry THF and slowly injected into the mixture. 
After 10 minutes the, the dry ice bath was taken away and the system was allowed to stir
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for 2 hours. The reaction was then quenched with double distilled H2O. The reaction 
system was then extracted with diethyl ether, dried over anhydrous sodium sulfate and 
the solvent was removed. Recrystallization was accomplished in ethyl acetate to give a 
white solid in a 67% yield; m.p. 87°C; *H NMR (200MHz, CDCI3) 1.01 (s, 9H) 2.98(s, 
3H) 3.47(s, 1H) 3.85(s, 1H) 4.91-4.93(d, 1H) 5.61(s, 1H) 7.25-7.38(m, 5H) 7.88- 
8.15(m, 9H)
3.6.7: Attempted synthesis o f Pyrenylalanine
0.075 g (0.0002 mol) of (2S,5R)-l-benzoyl-2-rer/-butyl-5-pyenyl-3-methyl-4- 
imidazolidinone was dissolved in 6M HClrglacial acetic acid. This was refluxed at 
110°C for 20 hours. NMR revealed starting material.
3.6.8: Synthesis of Schiffbase-ferf-butoxypyrenylalanine
0.27 g (0.0015 mol) of sodium bis(trimethylsilyi)amide was dissolved in dry THF 
under argon and cooled to -78°C with an acetone/dry ice bath. 0.44 g (0.0015 mol) of 
terf-Butylglycinate Schiff base was dissolved in dry THF and slowly injected into the 
solution. This was allowed to stir for 20 minutes. 0.4 g (0.0014 mol) of 
bromomethylpyrene was dissolved in THF and then slowly injected into the system. 
This was allowed to stir overnight. The reaction was then quenched with double 
distilled H2O, extracted with diethyl ether, dried over anhydrous sodium sulfate and the 
solvent was removed. Yield 72%; lH NMR (200 MHz, CDC13) 1.48 (s, 9H) 3.75-3.84 
(dd, 1H) 4.01-4.07 (dd, 1H) 4.44-4.49 (dd, 1H) 6.07 (d, 1H) 6.66-7.50 (m, 10H) 7.8- 
8.17 (m, 9H)
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3.6.9: Synthesis o f  Pyrenylalanine
1.1 g (0 .0 0 2 2  mol) of Schiffbase-terr-butoxypyrenylalanine was dissolved in 
THF. To this was added a catalytic amount of triisopropylsilane to act as a carbocation 
scavenger. 6  N HC1 was added and an immediate color change was noted. TLC noted 
one spot Rf =0.0 with a positive ninhydrin test. 1:1 glacial acetic acid:con HC1 was 
added and the mixture was extracted with diethyl ether. The aqueous layer was 
evaporated overnight to reveal a white crystalline product. This was dissolved in 
95%EtOH and, upon neutralization with propylene oxide, a white precipitate formed. 
65% yield; *H NMR (200MHz, DMSO-dfi) 3.33-3.55 (m, 2H) 4.07-4.12 (d, 1H) 7.98- 
8.47 (m, 9H)
3.6.10: Synthesis o f Fmoc-Pyrenylalanine
0.15 g (0.0005 mol) of pyrenylalanine was dissolved in 1:2 solution of 
10%Na2CC>3: Dioxane. 0.192 g (0.0006 mol) of fluorenylmethylcarbonyl sucinimide 
was directly added to the solution while stirring. The pH of the solution was adjusted to 
8 with the slow addition of triethyl amine and the solution was allowed to stir for 30 
minutes. The solution was then filtered and then acidified using 1 mol HC1 causing a 
white precipitate to fall out of solution. This precipitate was filtered and dried in a 
vacuum descicator overnight. TLC (9:1 CHCLiMeOH) has one spot at Rf= 0.2.Yield 
82%; *H NMR (200MHz, DMSO-de) 3.5-3.62(t, 1H) 3.93-4.15(m, 2H) 4.43(t, 1H) 
7.11-7.85 (m, 8H), 8.02-8.47 (m, 9H)
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3.7: Conclusion
The fluorescently labeled peptide was modeled on Sybyl on an Silicon Graphics 
Onyx workstation in order to determine how the pyrenes would align when the peptides 
aggregate in either parallel or antiparallel. If the peptides are aligned in a parallel 
fashion, the pyrenes would not be in proximity to one another to form an excimer in 
either a ground or excited state. When the peptides aggregate in an antiparallel fashion, 
then the pyrenes will align to be able to form an excimer in a ground or an excited state. 
In fact, the distance between the two pyrenes in an antiparallel aggregation state is 
between two and six angstoms. However, in the computation study, the peptides were 
placed in an aggregated state and not aggregated computationally and the aggregated 
peptides were not minimized.
In conclusion, the placement of one fluorescent probe in a peptide has given a 
wealth of information. The absorbance spectra showed that the probe was actually 
placed in the peptide and was used to give an accurate measurement of the 
concentration of the peptide via Beer’s law. The CD spectra of the labeled peptide is 
the similar to those without a fluorescent label. This is due to the presence of the 
pyrenylalanine. It also shows that the pyrenylalanine is within the a-helical portion of 
the peptide. Through solving of the equation mentioned in chapter 2, we found that the 
peptide is 81% a-helical. Finally by looking at the fluorescence spectra. There shows 
ground state excimer formation which can only occur when the peptides are aggregated 
in an antiparallel fashion.
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